We specialize in the evaluation and treatment of patients referred for blood and marrow stem cell transplants. Diseases treated:
- Leukemia (acute and chronic)
- Lymphoma (Hodgkin and non-Hodgkin)
- Multiple myeloma
- Myelodysplastic syndromes (MDS)
- Myelofibrosis
- Myeloproliferative neoplasms
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Primary amyloidosis
- Severe anaplastic anemia (SAA)
- Essential thrombocytosis (ET)
- Waldenström’s macroglobulinemia
- Sickle cell disease/anemia
- Adult inherited immunodeficiencies
- Testicular cancer
- Other hematologic diseases
Moffitt Cancer Center is a high-volume center, delivering more FDA-approved CAR T cell products than any other center in the nation. Current indications for CAR T cells are for patients with relapsed or refractory blood cancers, including:
Diseases Treated with Cellular therapy (FDA-Approved)
- Acute lymphoblastic leukemia
- B-cell non-Hodgkin lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Multiple myeloma
Diseases Treated with Stem Cell Transplant and Cellular Therapy
Indications for Allogeneic Hematopoietic Stem Cell Transplant
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Myelodysplastic syndromes
- Myelofibrosis and myeloproliferative diseases
- Systemic mastocytosis
- Blastic plasmacytoid dendritic cell neoplasm
- Hodgkin lymphoma
- Diffuse large B cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- T-cell lymphoma
- Chronic lymphocytic leukemia
Indications for Autologous Hematopoietic Stem Cell Transplant
- Multiple myeloma
- Hodgkin lymphoma
- Diffuse large B cell lymphoma
- Primary central nervous system lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- T-cell lymphoma
- Waldenstrom macroglobulinemia
- Burkitt lymphoma
- Germ cell tumor
Indications for Hematopoietic Stem Cell Transplant for Non-Malignant Conditions
- Severe aplastic anemia
- Pure red cell aplasia
- Thalassemia
- Sickle cell anemia
- Common variable immunodeficiency
- Multiple sclerosis
- Chronic granulomatous disease
Indications for Immune Effector Cell Therapy (FDA approved)
- Acute lymphoblastic leukemia
- Diffuse large B cell lymphoma
- Primary mediastinal B cell lymphoma
- High-grade B cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Multiple myeloma
Medically reviewed by Omar Castaneda Puglianini, MD
